Anbio Biotechnology NNNN

NASDAQ NNNN
$3.85 +0.58 (+17.74%)
As of: Oct 20, 2026 · 2:40 PM EDT

Anbio Biotechnology (NNNN) stock price is $3.85, up 17.74% on the day, as of Oct 20, 2026. It has a market cap of $170.76Mn and a P/E ratio of 22.51, and is classified in the Diagnostic Equipment industry (Healthcare sector).

Key Stats
Market Cap170.76 Mn
P/E22.51
P/S54.91
Div. Yield0.00
Add ratio to table…

About

Anbio Biotechnology is a medical technology company focused on the development and supply of in vitro diagnostic products. The company designs assays that detect biomarkers related to infectious diseases cancer cardiovascular conditions inflammation drug abuse endocrine disorders renal disease pharmacogenomics and diabetes. It works with third party laboratories to create the assays and then contracts manufacturers to produce the final products for sale. Revenue comes from…

Read more ↓
Sector: Healthcare Sector rationale Anbio Biotechnology develops and sells in vitro diagnostic products, including antigen tests and PCR products, which fall under the Medical Devices and Diagnostic Equipment industries within the Healthcare sector. Its primary customers are hospitals, clinics, and laboratories, and its revenue is derived from the sale of these medical diagnostic kits and instruments. Industry: Diagnostic Equipment Diagnostic Equipment Primary Anbio Biotechnology designs and sells in vitro diagnostic kits and instruments, including real-time PCR and chemiluminescence immunoassay products. Its revenue is derived from the sale of these diagnostic machines and the associated assays to hospitals, clinics, and laboratories. Classified using BQ-MICS CIK: 0001982708

Geographical Breakdown of Revenue (2025)

History
Peer percentiles

How Anbio Biotechnology ranks

Ranked against the 248 companies in Medical Devices and Diagnostics58 metrics · as of Oct 16, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/E 22.5xMedian 28.9x 89th
  • P/FCFNegative free cash flow −70.5xMedian 26.0x 55th
  • P/Operating cash flow —Median 20.1x No data —
  • P/S 54.9xMedian 3.07x 7th
  • P/B 15.7xMedian 2.40x 6th
  • P/Tangible book 15.7xMedian 3.05x 8th
  • EV/EBITDA —Median 18.0x No data —
  • EV/EBIT —Median 27.8x No data —
  • EV/Revenue —Median 3.25x No data —
  • EV/FCF —Median 26.6x No data —
  • EV/Operating cash flow —Median 21.9x No data —
  • PEG (3Y EPS CAGR) —Median 0.86 No data —
Peer group

Peer Comparison

Companies in the Diagnostic Equipment
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 255.02 Bn36.605.5042.55 Bn
2 ABT Abbott Laboratories 178.34 Bn32.873.8332.61 Bn
3 DHR Danaher Corp /De/ 157.53 Bn39.346.2726.56 Bn
4 ISRG Intuitive Surgical Inc 155.27 Bn49.4714.07-
5 MDT Medtronic plc 120.95 Bn23.123.2228.15 Bn
6 SYK Stryker Corp 116.89 Bn31.354.5214.94 Bn
7 BSX Boston Scientific Corp 66.99 Bn18.233.1912.62 Bn
8 NNNN Anbio Biotechnology 0.17 Bn22.5154.91-